BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has completed its review of the Company’s listing application and approved the Company’s common stock for listing on The Nasdaq Capital Market. The Company’s common stock is expected to begin trading on Nasdaq on August 7, 2026 under the ticker symbol "BSEM."

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.